The cancer tissue diagnostics market is projected to reach US$ 3,640.87 million by 2028 from US$ 2,538.31 million in 2022; it is estimated to grow at a CAGR of 6.2% from 2022 to 2028.
Cancer tissue diagnostics techniques are used to detect a tumor in malignant tissues. In the last few years, immunohistochemistry (IHC) was used to increase the detection of specific antigens in tumor tissue. With the help of nonfluorescent chromogens, the screening is analyzed with conventional microscopy. There are recent techniques developed for cancer tissue diagnosis. Fluorescence in situ hybridization is used to examine a genetic abnormality in the genome. The hybridized deoxyribonucleic acid (DNA) is examined with particular probes.
The cancer tissue diagnostics market is segmented on the basis of test type and geography. Based on test type, the market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. The market in the same segment is also anticipated to grow at a faster rate in the coming years. By geography, the cancer tissue diagnostics market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in Asia Pacific is expected to grow at the highest rate during the forecast period owing to the rising prevalence of cancer and the increasing aging population in Asian countries. The Japanese Government has been formulating and laying down multiple initiatives and programs to enhance the quality of cancer treatment and increase awareness regarding cancer in the country. In China, as per data by the WHO, 45,68,754 new cancer cases were detected, and 30,02,899 cancer deaths were recorded in the country in 2020. The cancer tissue diagnostics report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, market dynamics, and the competitive analysis of the globally leading market players.
Strategic Insights
Lucrative Regions for Cancer Tissue Diagnostics Market
(image)
Market Insights
New Product Launches and FDA Approvals and growing investments in Cancer Tissue Diagnostics to Fuel Cancer Tissue Diagnostics Market During Forecast Period
Most major market players are involved in manufacturing a wide range of cancer diagnostics products offering maximum advantages and early diagnosis. In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies. Thus, the constant technological developments in diagnostics and FDA approvals accelerate the market growth.
Furthermore, tissue diagnostics is crucial in cancer treatment. Cancer tissue diagnostics play a significant role in determining the treatment pace and procedure. Early detection can help reduce the mortality rates of cancer; hence, medical professionals, market players, and government authorities implement new diagnostics and treatment facilities. Thus, the rise in investments and better policies of reimbursement favor the growth of the cancer tissue diagnostics market.
In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN). Furthermore, In January 2020, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed. In 2019, the company launched AIforia cloud platform that accelerates image processing and provides automated pathology image analysis. Thus, the increasing collaborations and new technological platforms in cancer tissue diagnostics have led to the advent of breakthrough techniques, which are expected to fuel the growth of the market in the coming years.
Test Type-Insights
Based on test type, the cancer tissue diagnostics market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. In addition, the market in the same segment is expected to grow at a faster rate in the coming years owing to the cost-effectiveness of the technique. Moreover, the technique is easily accessible, and growth in the number of products based on technology are further expected to drive the segment growth.
(image)
Product launches and collaborations are highly adopted strategies by the global cancer tissue diagnostics market players. A few of the recent key market developments are listed below:
- In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
- In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies.
- In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
- In January 2020, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed.
- In June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to identify patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.
- In June 2019, Thermo Fisher Scientific's Oncomine Dx Target Test received reimbursement coverage from Japan's Ministry of Health, Labour and Welfare. The test is now commercially available in Japan. The reimbursement has helped the company to offer the diagnosis of NSCLC.\
- In May 2019, Roche launched the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, an in vitro diagnostic ROS1 immunohistochemistry (IHC) assay. The launch has enabled the company to offer better innovative products.
Company Profiles
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Bio Rad Laboratories Inc
- Abbott
- Enzo Life Sciences, Inc
- Agilent Technologies, Inc
- Cancer Genetics Inc
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher Corporation
- Abcam plc.